ChAdOx1 MERS Vaccine Description
ChAdOx1 MERS is a vaccine candidate to treat MERS Coronaviruses (CoV). The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.
Vaccitech’s partner, the University of Oxford’s Jenner Institute, in collaboration with The King Abdullah International Medical Research Centre (KAIMRC), announced on December 20, 2019, that it has started a Phase I clinical trial in the Kingdom of Saudi Arabia (KSA) for a vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Vaccitech retains commercial rights to this vaccine.
The patented Vaccitech adenovirus vectors are known as chimpanzee adenovirus Oxford 1 and 2 (ChAdOx1 and ChAdOx2), and are in the group E simian adenovirus family, similar to the widely-studied chimpanzee adenovirus 63. These viruses have been engineered to be replication-deficient and can be manufactured in well-established HEK293 cell lines containing the adenoviral E1 gene.
Vaccitech has licensed the needed patents from Oxford University to advance all of the programs. ChAdOx1 vector patent was granted in the US and the EU, and our MVA-NP+M1 patent is granted in the EU and pending in the US.
ChAdOx1 MERS Coronavirus Vaccine Indication
ChAdOx1 is a vaccine candidate indicated to protect people against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the novel SARS-CoV-2 coronavirus.
ChAdOx1 MERS Coronavirus Vaccine Clinical Trials
- Clinical Trial NCT04170829: A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine. This research was funded by the Department of Health and Social Care (project number:16/107/01) as part of the UK Vaccine Network (UKVN), a UK Aid program to develop vaccines for diseases with epidemic potential in low and middle-income countries.
- Clinical Trial NCT03399578: Safety and Immunogenicity of a Candidate MERS-CoV Vaccine.
- April 20, 2020 - Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomized, uncontrolled, phase 1 trial.
- April 17, 2020 - Investigational chimp adenovirus MERS-CoV vaccine protects monkeys.
CONTENT SOURCES: World Health Organization, US Centers for Disease Control and Prevention, clinicalTrials.gov, and the Precision Vaccinations news network.